Peer-reviewedCC BYMinia Journal of Medical Research1 Oct 2026

Live Birth Outcomes Following subendometrial platelet rich plasma versus Intrauterine platelet rich plasma infusion in Women with Recurrent Implantation Failure: A Cohort Study

Mohammed Saber¹
Abdelbaset Abdelbaset²
Ahmed Abdelmalik²
Enas Mohammed³

¹Department of Obstetrics and Gynecology, Faculty of Medicine ,Minia University
²Department of Obstetrics and Gynecology, faculty of medicine, Minia University
³department of Obstetrics and Gynecology, faculty of medicine minia University

Abstract

Background: Clinical pregnancy rate is the outcome most commonly reported in trials of platelet-rich plasma (PRP) as an adjunct for recurrent implantation failure (RIF) [6-11], yet live birth — the outcome of greatest relevance to patients — is rarely assessed. Objective: To determine live birth rate, miscarriage rate, and pregnancy continuation among women who achieved clinical pregnancy after sub-endometrial PRP injection (SE-PRP), intrauterine PRP infusion (IU-PRP), or standard hormonal preparation alone (control), as a follow-up of a previously completed three-arm randomized controlled trial [1]. Methods: This follow-up cohort study traced pregnancy outcome for all 59 women who achieved clinical pregnancy in the parent trial [1] (SE-PRP = 24, IU-PRP = 20, control = 15) through to delivery or pregnancy loss. Results: Live birth occurred in 15/60 (25.0%) in the SE-PRP group, 12/60 (20.0%) in the IU-PRP group, and 8/60 (13.3%) in the control group (χ² = 2.62, p = 0.27). Among women who achieved clinical pregnancy, live birth rate was 62.5%, 60.0%, and 53.3% respectively (p = 0.85), with no significant between-group difference in pregnancy continuation once implantation had occurred. Conclusion: Live birth rate followed the same numerical hierarchy (SE-PRP > IU-PRP > control) observed for clinical pregnancy in the parent trial [1], though the difference did not reach statistical significance. The similarity in pregnancy-continuation rate across groups suggests that the principal contribution of PRP — and of its delivery route — operates at the level of implantation rather than throughout gestation.

Beyond the Embryo: Rethinking the Genetics of Recurrent Implantation Failure in the PGT-A Era
Charalampos Voros, Fotios Chatzinikolaou, George Papadimas +11
Genes23 Sep 2026Peer-reviewedCC BYFull textGenetics & genomicsEurope PMC
Recurrent implantation failure: a registry-corroborated, age-stratified definition and pragmatic five-tiered management algorithm.
Hossam Elzeiny, Alexander M Quaas, Alexandra P Bielfeld +1
Frontiers in endocrinology5 Oct 2026Peer-reviewedCC BYFull textImmunologyEurope PMCCrossref
Autophagy as a potential link between progesterone responsiveness and endometrial immune function in recurrent implantation failure
Li Guo, Jinghong Xie, Mengyu Wang +3
Frontiers in Immunology12 Oct 2026Peer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMC
Altered IRE1α-Dependent Decidual Programming Links Impaired Inflammation and Angiogenesis in Recurrent Implantation Failure.
Lara Castagnola, Lourdes Materazzi, Daniel Paparini +13
Biology23 Sep 2026Peer-reviewedCC BYFull textImmunologyEurope PMC
Liquid Biopsy as a Screening Tool in Recurrent Implantation Failure During IVF: A Narrative Review.
Reza Saeedinia, Ava Hemmat, Zohreh Heidary
Journal of family & reproductive health1 Jun 2026Peer-reviewedCC BY-NCFull textImmunologyEurope PMC

Cite

BibTeX RIS

BibTeX

@article{saber2026live,
  title = {{Live Birth Outcomes Following subendometrial platelet rich plasma versus Intrauterine platelet rich plasma infusion in Women with Recurrent Implantation Failure: A Cohort Study}},
  author = {Mohammed Saber and Abdelbaset Abdelbaset and Ahmed Abdelmalik and Enas Mohammed},
  journal = {Minia Journal of Medical Research},
  year = {2026},
  month = oct,
  doi = {10.21608/mjmr.2026.537183.2407},
  url = {https://doi.org/10.21608/mjmr.2026.537183.2407},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Live Birth Outcomes Following subendometrial platelet rich plasma versus Intrauterine platelet rich plasma infusion in Women with Recurrent Implantation Failure: A Cohort Study
AU  - Mohammed Saber
AU  - Abdelbaset Abdelbaset
AU  - Ahmed Abdelmalik
AU  - Enas Mohammed
PY  - 2026
DA  - 2026/10/01
JO  - Minia Journal of Medical Research
DO  - 10.21608/mjmr.2026.537183.2407
UR  - https://doi.org/10.21608/mjmr.2026.537183.2407
AB  - Background: Clinical pregnancy rate is the outcome most commonly reported in trials of platelet-rich plasma (PRP) as an adjunct for recurrent implantation failure (RIF) [6-11], yet live birth — the outcome of greatest relevance to patients — is rarely assessed. Objective: To determine live birth rate, miscarriage rate, and pregnancy continuation among women who achieved clinical pregnancy after sub-endometrial PRP injection (SE-PRP), intrauterine PRP infusion (IU-PRP), or standard hormonal preparation alone (control), as a follow-up of a previously completed three-arm randomized controlled trial [1]. Methods: This follow-up cohort study traced pregnancy outcome for all 59 women who achieved clinical pregnancy in the parent trial [1] (SE-PRP = 24, IU-PRP = 20, control = 15) through to delivery or pregnancy loss. Results: Live birth occurred in 15/60 (25.0%) in the SE-PRP group, 12/60 (20.0%) in the IU-PRP group, and 8/60 (13.3%) in the control group (χ² = 2.62, p = 0.27). Among women who achieved clinical pregnancy, live birth rate was 62.5%, 60.0%, and 53.3% respectively (p = 0.85), with no significant between-group difference in pregnancy continuation once implantation had occurred. Conclusion: Live birth rate followed the same numerical hierarchy (SE-PRP > IU-PRP > control) observed for clinical pregnancy in the parent trial [1], though the difference did not reach statistical significance. The similarity in pregnancy-continuation rate across groups suggests that the principal contribution of PRP — and of its delivery route — operates at the level of implantation rather than throughout gestation.
SN  - 2682-4558
ER  -

Abstract

Related

Cite